Key facts
- Kiyatec’s last known valuation is $62.1M (May 2023).
- It has raised $32.9M across 4 recorded rounds; the latest was Seed Round ($250K) in Oct 2024.
- Notable investors include Labcorp Venture Fund, SC Launch, Seae Ventures, Atlanta Technology Angels, Abhishek Narang — 20 tracked in total.
- Kiyatec has filed 10 Form Ds with the SEC since 2012, most recently Nov 2024 ($250K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Kiyatec
Funding rounds
4 roundsAbout Kiyatec
Developer of patient-specific three-dimensional cell culture testing services designed to predict therapeutic response for cancer treatment selection. The company's testing technology evaluates individual patients' tumour responses ex vivo, enabling oncologists to identify effective therapies and avoid likely non-responders before treatment begins.
- Sector
- Healthcare
- HQ
- Greenville, SC, United States
- Founded
- 2005
- Employees
- 15
- Website
- kiyatec.com/
- Ownership
- Privately Held (backing)
Kiyatec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kiyatec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kiyatec in its N-PORT filings yet. We sweep new filings monthly.